ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,996.66
1.00%
US Tech 100
20,877.20
1.72%
다우존스 지수
43,487.83
0.78%
Bitcoin
103,656.87
-0.45%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) 뉴스

RVNC

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:RVNC
일자시간출처헤드라인심볼기업
2025/01/1722:15Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2025/01/1619:45PR Newswire (US)Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCNASDAQ:RVNCRevance Therapeutics Inc
2025/01/1406:18Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2025/01/1322:44Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2025/01/1322:30PR Newswire (US)Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.NASDAQ:RVNCRevance Therapeutics Inc
2025/01/1319:45PR Newswire (US)Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:RVNCRevance Therapeutics Inc
2025/01/1106:52Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RVNCRevance Therapeutics Inc
2025/01/0919:45PR Newswire (US)The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNCNASDAQ:RVNCRevance Therapeutics Inc
2025/01/0623:00Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2025/01/0623:00PR Newswire (US)Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in CashNASDAQ:RVNCRevance Therapeutics Inc
2025/01/0306:45Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2025/01/0306:36Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2024/12/1923:00Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2024/12/1222:01Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:RVNCRevance Therapeutics Inc
2024/12/1222:00PR Newswire (US)Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per shareNASDAQ:RVNCRevance Therapeutics Inc
2024/12/1221:15Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:RVNCRevance Therapeutics Inc
2024/12/1220:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/12/1007:16Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0923:24Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0923:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0922:30PR Newswire (US)Crown Laboratories and Revance Enter into Amended and Restated Merger AgreementNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0922:30Business WireCrown Laboratories and Revance Enter into Amended and Restated Merger AgreementNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0606:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0322:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/11/2920:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/11/2620:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/11/2006:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/11/2006:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/11/0806:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/11/0806:05Business WireRevance Reports Third Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
 검색 관련기사 보기:NASDAQ:RVNC

최근 히스토리

NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
USOTC
BASFY
BASF (QX)
USI
USTECH100
US Tech 100
NYSE
JPM
JP Morgan Chase
SPI
SP500
S&P 500
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
USDEUR
US Dollar vs Euro
NYSE
AXP
American Express
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
DOGEUSD
Dogecoin
NYSE
BAC
Bank of America
NYSE
XOM
Exxon Mobil
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유